PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2077982
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2077982
India Hemostat Market is estimated to be valued at USD 96.2 Mn in 2026 and is expected to reach USD 140.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 96.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.60% | 2033 Value Projection: | USD 140.9 Mn |
Hemostats, also referred to as hemostatic clamp, arterial forceps or pean are surgical tools used in surgical procedures to control bleeding. The hemostats were designed to clamp blood vessels of small size to manage blood flow in hemorrhagic cases. These devices are also used to grasp and secure superficial fascia during wound closure surgical procedures. The hemostats, with hinges and rings, are visibly similar to scissors. These instruments have a locking mechanism known as rachet that is used for clamping wherein the jaws of locking forceps come together, which helps in sealing the opening of the blood vessels. In many cases, the hemostats can be used to hold the subcutaneous tissues on the edges of the wound, while the tissue forceps are applied to the other edge to retract and gain better exposure to the wound site.
The prevalence of blood disorders leads to a boost in the India hemostat market .According to an article published in the Financila Express on May 9, 2023, with 42 Mn carriers, India is the Thalassemia capital of the world. At the same time , the huge costs of hemostats that use advanced microfibrillar technology cause patients from tier 2 and 3 cities to not receive appropriate treatment. According to an article published by PubMed-a free search engine for biomedical and life sciences data,people with insurance status (Medicare, Medicaid, commercial, self-pay, and unknown) do receive hemostats during surgical procedures in India. Thus, the Indian government is taking steps to assure adequate reimbursement since it recognises the importance of hemostats in the healthcare industry and their role in driving market growth over the forecast period.